Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and liver:

Search results

Items: 1 to 20 of 123

1.

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C.

Epilepsia. 2019 Feb 11. doi: 10.1111/epi.14670. [Epub ahead of print]

PMID:
30740695
2.

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

White CM.

J Clin Pharmacol. 2019 Feb 7. doi: 10.1002/jcph.1387. [Epub ahead of print] Review.

PMID:
30730563
3.

Decarbonylation: a metabolic pathway of cannabidiol in humans.

Kraemer M, Broecker S, Madea B, Hess C.

Drug Test Anal. 2019 Jan 30. doi: 10.1002/dta.2572. [Epub ahead of print]

PMID:
30698361
4.

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.

Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C.

Epilepsia. 2019 Feb;60(2):294-302. doi: 10.1111/epi.14628. Epub 2018 Dec 23.

PMID:
30582156
5.

Epilepsy and Cannabis: A Literature Review.

Zaheer S, Kumar D, Khan MT, Giyanwani PR, Kiran F.

Cureus. 2018 Sep 10;10(9):e3278. doi: 10.7759/cureus.3278. Review.

6.

Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells.

Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, Holzmann K, Lavorgna M, Isidori M, Knasmüller S.

Arch Toxicol. 2019 Jan;93(1):179-188. doi: 10.1007/s00204-018-2322-9. Epub 2018 Oct 19.

7.

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome.

McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, McDonald K, Zhang G, Sharma R, Whitney R, Sinopoli K, Snead OC 3rd.

Ann Clin Transl Neurol. 2018 Aug 1;5(9):1077-1088. doi: 10.1002/acn3.621. eCollection 2018 Sep.

8.

Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.

Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, Shah N, Wu L, Haq K, Solanki S, Kim D, Ahmed A.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):149-156. doi: 10.1097/MEG.0000000000001263.

PMID:
30234644
9.

Cannabis in liver disorders: a friend or a foe?

Goyal H, Rahman MR, Perisetti A, Shah N, Chhabra R.

Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1283-1290. doi: 10.1097/MEG.0000000000001256. Review.

PMID:
30169449
10.

Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience.

Chen KA, Farrar M, Cardamone M, Gill D, Smith R, Cowell CT, Truong L, Lawson JA.

Med J Aust. 2018 Aug 3;209(5):217-221. Epub 2018 Aug 13.

PMID:
30092753
11.

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group.

N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631.

12.

Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay.

Cuñetti L, Manzo L, Peyraube R, Arnaiz J, Curi L, Orihuela S.

Transplant Proc. 2018 Mar;50(2):461-464. doi: 10.1016/j.transproceed.2017.12.042.

PMID:
29579828
13.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group.

Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14.

14.

Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury.

Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Haskó G, Mechoulam R, Gao B, Pacher P.

Sci Rep. 2017 Sep 21;7(1):12064. doi: 10.1038/s41598-017-10924-8.

15.

Cannabinoids as Anticancer Drugs.

Ramer R, Hinz B.

Adv Pharmacol. 2017;80:397-436. doi: 10.1016/bs.apha.2017.04.002. Epub 2017 Jun 12. Review.

PMID:
28826542
16.

Interactions between cannabidiol and commonly used antiepileptic drugs.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program.

Epilepsia. 2017 Sep;58(9):1586-1592. doi: 10.1111/epi.13852. Epub 2017 Aug 6.

17.

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group.

N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618.

18.

Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines.

Arellano AL, Papaseit E, Romaguera A, Torrens M, Farré M.

CNS Neurol Disord Drug Targets. 2017;16(5):554-566. doi: 10.2174/1871527316666170413104516. Review.

PMID:
28412920
19.

Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.

Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, Laish I, Benjaminov F, Konikoff FM.

Dig Dis Sci. 2017 Jun;62(6):1615-1620. doi: 10.1007/s10620-017-4540-z. Epub 2017 Mar 27.

PMID:
28349233
20.

Potential of Cannabidiol for the Treatment of Viral Hepatitis.

Lowe HI, Toyang NJ, McLaughlin W.

Pharmacognosy Res. 2017 Jan-Mar;9(1):116-118. doi: 10.4103/0974-8490.199780.

Supplemental Content

Loading ...
Support Center